Introduction
Radiopharmaceutical chemistry, besides the medicinal rationale, is undoubtedly the driving force behind tracer development for in vivo molecular imaging. Devising new radiochemical methodologies to introduce radioisotopes into organic molecules of various molecular weights and chemical nature has been a continuing strife throughout the history of radioactive probe development. In principle, almost any organic compound can be radioactively labeled depending on the nuclide, the acceptable level of derivatization which is necessary particularly in radiometal labeling, and of course the position of the label itself. With the contingent of existing labeling methods, it is possible to label nearly all compounds in sufficient radiochemical yields (RCYs); however, sometimes the required great technical effort can prevent clinical routine production. Currently, only radiochemistries based on coordinating radiometals such as technetium-99m ( 99m Tc), which accounts for the majority of all radiopharmaceuticals produced for single-photon emission computed tomography (SPECT), as well as indium-111 ( 111 In, for SPECT), gallium-68 ( 68 Ga), and copper-64 ( 64 Cu) both for positron emission tomography (PET) proceeds in a kit-like manner [1] [2] [3] [4] . In particular, 99m Tc radiochemistry evolved over decades into fully GMP compliant (Good Manufacturing Practice) labeling kits where a simple addition of the radionuclide in the chemical form of its pertechnetate ( 99m TcO 4 − ) followed by very few simple steps yields the tracer. For other radiometals, final HPLC purification is sometimes inevitable and the operators in the laboratory have to possess a certain degree of technical proficiency and equipment in order to deliver an injectable solution that complies with GMP regulations. Additional obstacles exist for radiolabeling with the most extensively used PET isotope 18 F. The interest towards the development of 18 F-radiopharmaceuticals ensues essentially from the low positron energy (635 KeV) and the most suitable half-life (109.7 min) of this radioisotope. As a consequence, 18 F is ideal for numerous PET imaging applications involving tracers of low molecular weight as well as various biomolecules with a suitable kinetic profile. In particular, the successful and widespread use of [ 18 F]2-fluoro-2-deoxy-D-glucose ([ 18 F]FDG) has ignited the interest in new 18 F-tracers but despite its favorable nuclear properties, 18 F-radiochemistry remains often associated with relatively cumbersome and lengthy labeling procedures. Indeed, 18 Flabeling normally involves relatively large precursor quantities and often requires high reaction temperatures as well as the presence of activating reagents (e.g., strong bases plus cryptands) leading to unwanted radioactive and chemical side products, which need to be thoroughly separated from the desired 18 F-labeled tracer. Consequently, there are only few examples published in the literature where the radiochemical labeling procedure does not require a final HPLC purification. This is problematic due to the need for fully GMP compliant synthesis modules, which led manufacturers to search for solid phase based purifications to circumvent HPLC procedures [5] [6] [7] . Moreover, the classical use of harsh reaction conditions precludes a direct 18 F-radiolabeling of complex biomolecules not able to withstand those reaction conditions. In such cases, the use of 18 F-carbon-based prosthetic groups is often necessary, imposing further equipment challenges in addition to the time-consuming aspects.
The recent development of comparatively simple, efficient, and innovative labeling approaches based on silicon-18 F [5, [8] [9] [10] 18 F-labeling strategy was initially coined in reference to the isotopic exchange (IE) approach introduced by Schirrmacher et al. [5] (Scheme 1). A more inclusive definition of SiFAs also comprises the alkoxysilane leaving group approach introduced by Choudhry et al. [20] which was expanded to hydrosilanes and silanols by the group of Ametamey [21] . The current review will detail and discuss the technical developments and applications which have led to the current status of [
18 F]-SiFA radiochemistry as a simplified approach towards new radiopharmaceuticals for PET imaging.
SiFA Labeling Chemistry
Formation of Si-F bonds is driven by the strong affinity between silicon and fluorine as exemplified by the high [27, 28] .
In a more recent study, the group of Perrin provided an innovative approach towards 18 (Figure 1(a) ). Yet, important distinctions exist between the two techniques, one of which resides in the fact that the IE typically proceeds at room temperature or below while the Si-leaving group approach, like aliphatic and aromatic 18 F-carbon radiochemistry in general, necessitates elevated temperatures which may be detrimental when direct labeling of biomolecules is considered.
The efficiency of the IE, even at low temperatures, can be attributed to the low energy barrier for the 19 (Figure 1(b) , upper path) [29] .
On the other hand, in the gas phase, values of Δ ‡ of −50
to −40 kcal mol −1 were calculated in agreement with the expected formation of thermodynamically stable organofluorosiliconates (Figure 1(b) , lower path) [30, 31] . Those energetic differences ensue from the diminished Lewis basicity of the fluoride anion in acetonitrile compared to that in the gas phase, suggesting that in the former case equilibrium is rapidly reached leading to the fast and near- proceeds quasi-quantitatively in many instances even at low temperatures [32] . In contrast,
18 F-radiofluorination of more stable silanol precursors [33] (or other leaving group bearing silanes) should be endergonic (Δ > 0) and associated with less stable hydrosiliconate intermediates in both gaseous and condense phases as expected from bond dissociation energies (BDEs).
An additional important distinction between IE and the leaving group method relates to purification techniques. Since the IE involves chemically identical entities and proceeds under mild conditions that do not lead to side products, HPLC purification can often be avoided and purification can be limited to solid phase cartridge extraction (SPE). This approach is feasible irrespective of the nature of the tracer (e.g., small fragments or biomolecules). In contrast, HPLC purification constitutes a prerequisite of the leaving group approach as chemically distinct precursors and 18 F-radiolabeled products have to be carefully separated.
Nevertheless, this method has been thoroughly developed and adapted frequently by the radiochemistry community. Since the initial contribution of Choudhry et al., the group of Ametamey and coworkers has further extended the siliconleaving group approach methodology to hydride, hydroxy, and alkoxy leaving groups. 
Scheme 3: Postulated mechanism for rate enhancement in silicon fluorination using a crown ether leaving group by Al-huniti et al. conditions (gray = carbon; red = oxygen; dark green = silicon; cyan = fluoride; purple = potassium; hydrogen omitted for simplicity).
of O-bearing leaving groups but did not modify hydride rate departure from precursor 13. In a recent study, the leaving group SiFA methodology was combined with the nucleophile assisting leaving group (NALG) strategy to generate Si-appended potassiumchelating SiFA-based leaving groups [34, 35] . In the absence of added Kryptofix 2.2.2, the facilitation of 18 F-fluorination in the presence of cyclic crown ethers such as in 17 compared to acyclic polyethers or alkoxide leaving groups was clearly established. Unfortunately, the RCYs were undermined by the limited solubility (1-5%) of nca K 18 F in the reaction media. This issue was partially addressed by water addition (up to 0.5% v/v) leading to an increased K 18 F solubility (31%), but further addition subsequently diminished the observed RCYs. Consequently, upon optimized conditions, [ 18 F]7 was obtained in overall 10% RCY (Scheme 3). Thus, despite being conceptually elegant and promising, this approach is significantly hampered by 18 F − solubility issues which will possibly be addressed in the future to establish this methodology as a practical alternative to the simpler and straightforward SiFAleaving group method or IE methodology. the development of lipophilicity-reducing auxiliaries which will be discussed in Section 4. Further confirmation of the importance of sterically demanding SiFA substituents was provided by the detailed and systematic investigation on hydrolytic stability led by Höhne et al. (Table 1 ) [33] .
SiFA Lipophilicity and Hydrolytic Stability
The observed trends strongly correlate with the steric nature of the silicon substituents. In particular, the presence of bulky tert-butyl groups, combined with an aryl linker moiety, result in remarkable stability whereas smaller alkyl substituents progressively enhance the hydrolysis rate. Furthermore, the authors also provided a detailed hydrolysis mechanism (Scheme 4) as well as a theoretical model based on the difference in Si-F bond lengths (Δ (Si−F) ) between the starting SiFA structures (A) and the DFT optimized intermediate structure (D) (where Δ (Si−F) ≥ 0.19Å corresponds to hydrolytically unstable SiFAs). [36] . They suggested that this conversion proceeds with an analogous mechanism to the one encountered in the hydrolysis ofketosilanes following treatment with water [37] . This interestingly constitutes the first example of a SiFA hydrolytic stability issue involving the cleavage of the silicon-carbon bond. Figure 4 : Structures of SiFA building blocks amenable to IE and peptide labeling.
[ 18 F]SiFA Labeling of Peptides
PET probes for in vivo imaging [38] [39] [40] but it is inherently hampered by its technical complexity, harsh reaction conditions, and time-consuming HPLC purifications. Simplifying such procedures by means of mild and efficient radiolabeling approaches without HPLC purifications at one or all synthetic stages while maintaining sufficient SA represents an important challenge in 18 F-PET radiochemistry. The [ 18 F]SiFA method, as well as other promising emerging technologies such as the Al-18 F approach [14] [15] [16] [17] [18] [19] , is particularly well suited to address those classical limitations. Figure 4 presents various synthesized SiFA building blocks bearing reactive groups for peptide conjugation (for proteins and small molecules vide infra) [6, 32, [41] [42] [43] [44] [45] . The coupling of those SiFAs to peptides prior to the IE labeling would in theory allow for a direct and mild 18 F-incorporation without subsequent HPLC purification. Indeed, this was early demonstrated by Schirrmacher et al. [5] with the direct radiosynthesis of [ efficiency of 95-97% and 57-66% isolated RCYs (nondecay corrected), the approach suffered from low SAs (0.08-0.14 Ci mol −1 ). Subsequently, a two-step procedure which consists of the near quantitative initial fluorination of the aldehyde [
18 F]37 (Scheme 7) in high SAs (>5000 Ci/mmol), followed by a rapid C-18 SPE purification and subsequent room temperature conjugation to N-terminal amino-oxy functionalized Tyr 3 -octreotate, was reported [29] (Table 2 recapitulates selected examples of SiFA-peptide labeling). In the same study, the [
18 F]37 synthon was also efficiently applied to the labeling of a cyclic RGD (Arg-Gly-Asp) and a PEG-conjugated bombesin (BBN) analogue (cyclo(fK(AO-N)RGD and BZH3, resp.). In parallel, important progress towards the direct fluorination of bioactive peptides from hydrosilanes and silanol precursors following the leaving group approach was made. The initial report by Mu et al. illustrates the methodology with the synthesis of two 18 F-labeled tetrapeptides. The reactions proceeded at 65-90 ∘ C with moderate incorporation of 18 F from either of the hydrosilane and the silanol (45% and 53%, Via isotopic exchange (IE) either direct or in two steps or via the leaving group approach from the specified precursor.
b The RCYs are reported as isolated end of synthesis (eos) yields either decay correct (dc) or not (ndc); in the absence of available RCYs at eos, incorporation RCYs are reported. resp.) [21] . The importance of the bulky tBu 2 Ph-SiFA motif to guarantee hydrolytic stability was confirmed once more. Both an iPr 2 Ph-SiFA bombesin analogue [33] and two alkyllinked iPr 2 -SiFA model tripeptides were shown to be unstable (pH 7.5, phosphate buffer) [46] (Figure 5 ). Following the leaving group approach, the development and first in vivo evaluation of a [
18 F]SiFA labeled bombesin analogue in PC3 xenografted nude mice were subsequently reported [9, 33] ( Table 2 , Entry 7). The authors reported low uptake in gastrinreleasing peptide receptor (GRP) positive tumor bearing mice and high unspecific binding along with prominent hepatobiliary excretion, despite sufficient potency (IC 50 = 22.9 nM) based on comparison with previously characterized successfully radiolabeled BBN analogues. The observation of gradually increasing but overall low bone uptake suggested that di-tert-butyl aryl [
18 F]SiFA was sufficiently stable in vivo. Hence, the poor pharmacokinetic profile observed was reasonably ascribed to the overall high lipophilicity of the probe imparted by the SiFA moiety.
Wängler et al. reported the synthesis, HPLC-free purification, and in vivo evaluation of carbohydrate and carbohydrate/PEG derivatized [
18 F]SiFA-octreotate probes for imaging sst2-expressing tumors (AR42J xenografts; Table 2 ; Entries 3 and 4). [47] . This study, based on the previously (Table 2 ) and the in vivo PET evaluation suggested that the tracer might be useful in the determination of v 3 integrin expression as significant tumor uptake was reported.
Secondly, the group of Ametamey introduced another lipophilicity reducing strategy towards the development of optimized [
18 F]SiFA bombesin analogues [36] . The synthesis of tartaric acid/l-cysteic acid-containing linked BBN derivatives allowed for a significant lipophilicity reduction (log D 7.4 = 0.3 ± 0.1 for [
18 F]54 versus 1.3 ± 0.1 for cysteic acid free peptide-entry 7, Table 2 ). The in vivo evaluation of the most potent derivative [
18 F]54, which was labeled in low overall RCY of 1.8% from the hydrosilane 53, demonstrated that the positive physicochemical alteration introduced by the hydrophilic auxiliary correlated with improved imaging properties (Scheme 8). Enhanced tumor accumulation and tumor-to-blood ratio were detected in PC-3 xenografted mice compared to the lipophilic [ 18 F]SiFA-BBN probe. [44] . Remarkably, and despite the high reactivity of the isothiocyanate fragment, the IE proceeded nearly in quantitative yields (95% RCY; rt; 10 min) and allowed for the efficient direct synthesis of various 18 F-labeled model proteins (RSA, apotransferrin, and bovine IgG) in suitable SAs (2.7-4.5 Ci mol −1 ).
[ 18 F]SiFA Protein Labeling
Subsequently, the decomposition of active esters such as [
18 F]SiFB ([ 18 F]46) during radiolabeling due to the basicity of the reaction mixture (potassium oxalate/hydroxide) was resolved by addition of a suitable amount of oxalic acid in order to neutralize the base present during the labeling procedure [42] . This study showed the feasibility of the cartridge-based synthesis of [ Figure 6 ).
This procedure is fast (3-5 min) and fully devoid of azeotropic drying and is easily implemented into an automated setup. The recent implementation of the "Munich method" alongside the SiFA-IE labeling approach for peptide and protein labeling [43, 46, 58, 59] 
Small Molecules
It has previously been shown that, in the absence of suitable auxiliaries, the intrinsic lipophilicity introduced by the SiFA moiety often results in significant alteration of the overall physicochemical properties and in vivo biodistribution of the bioactive compound to which they are bound. This is especially true for ligands with low molecular weight. Nevertheless, certain groups have studied 18 F-radiolabeled silicon-based small ligands for PET imaging and, in some cases, obtained preliminary useful in vivo PET data.
An initial study by Bohn et al. and a follow-up investigation by Joyard et al. demonstrated the synthesis, radiolabeling, and in vivo evaluation of silicon-based analogues of [
18 F]FMISO, an established tracer for detection of hypoxia [62, 63] . In spite of the well-known steric requirements of the silicon atom, the authors described a series of alkyl substituted [ 18 F]SiFA-FMISO analogues which resulted in insufficient hydrolytic stability both in vitro and in vivo (Table 3 ; Entries 1 and 2). Accordingly, the dimethyl [
18 F]SiFA MISO compound ( 1/2 < 5 min) only showed poor tumor uptake in mice while radioactivity accumulation occurred rapidly and significantly in bones due to the in vivo liberation of 18 F − . The more stable dinaphthyl derivative ( 1/2 = 125 min) (Entry 4, Table 3 ) was retained in pulmonary capillaries due to its high lipophilicity (cLog P = 6.47). After evaluating other unstable derivatives, the authors described the synthesis and evaluation of a promising tBu 2 Ph-based [
18 F]SiFA tracer (Entry 7, The most recent contribution from Hazari et al. describes the design and evaluation of a highly potent and selective 5-HT 1A homodimeric SiFA-dipropargyl glycerol derivatized radioligand aimed at PET imaging of dimeric serotonin receptors ( Figure 9; [ 18 F]65) [66] . This multimeric approach is supported by the development of bivalent 5-HT ligands based on recent evidence suggesting that some 5-HT receptors exist as dimers/oligomers [67] . The tracer, [ 18 F]BMPPSiF, was obtained following the leaving group approach from the corresponding hydrosilane. The synthesis of the precursor was achieved via double azide-alkyne Huisgen cycloaddition with two azidoethyl (2-methoxyphenyl)piperazine fragments. Subsequent 18 F-radiofluorination occurred in 52 ± 10.5% RCY upon heating to yield [
18 F]BMPPSiF with a SA of 13 Ci mol −1 . Brain PET imaging in rats showed high uptake in 5-HT 1A receptor rich regions. As expected, significant reduction of the uptake in the hippocampus was detected in serotonin-depleted rat models. Blocking studies did not reveal significant decrease in uptake. Notably, this report constitutes the first example of a SiFA-small ligand with positive PET imaging data. Interestingly, it also suggests that when applicable, [ 18 F]SiFA-based multimeric derivatization may help compensate the overall influence on physicochemical parameters of the SiFA moiety on small ligands.
SiFA: A Critical Assessment
From the very first appearance of SiFA compounds in 2006 and 2008 the groups of Ametamey and Schirrmacher/Wängler/Jurkschat have put extensive efforts into the structural optimization of the SiFA building blocks. The main drawback of this labeling technique irrespective of the actual labeling methodology (IE or leaving group approach) is the inherently extremely high lipophilicity hampering in vivo application in general. The compounds of the first generation when injected into animals were almost exclusively metabolized by the hepatobiliary system which lead to a high liver uptake and almost zero uptake in the target tissue. Both groups have approached this problem by introducing hydrophilic components into the SiFA tagged molecules to compensate for the high lipophilicity. However, this strategy is only useful for larger biomolecules such as peptides and proteins which tolerate an extensive structural modification. It could be convincingly demonstrated by Niedermoser et al. recently that highly hydrophilic SiFA derivatized somatostatin analogues can be labeled in a one-step reaction via IE in high RCYs and SAs of 1200-1700 Ci/mmol [68] . High IC 50 values of the SiFA-peptides in the low nanomolar range and a very high tumor uptake of >15% in a AR42J nude mice tumor model showed that the lipophilicity problem has been successfully solved, paving the way for a human clinical application in the near future. The most recently published paper by Lindner at al. demonstrated that SiFA tagged RGD peptides can serve as tumor imaging agents in a mouse U87MG tumor model if hydrophilic auxiliaries are added in combination with the SiFA labeling moiety [69] . A tumor uptake of 5.3% ID/g was observed, clearly delineating the tumor from other tissues. Unfortunately smaller molecules lend themselves less towards a SiFA labeling because of the difficulty of compensating for the SiFA lipophilicity. A small molecule such as a typical receptor ligand for brain imaging does not accept considerable structural modifications to adjust the SiFA lipophilicity without seriously compromising its binding properties to the target receptor. It is therefore unlikely that the SiFA labeling technique will grow into a staple for labeling molecules of small molecular weight. It is also true that all compounds reported so far have been only used in animal experiments. The SiFA methodology still has to prove its usefulness in a human clinical setting. This however requires extensive efforts and financial commitments from the academic research groups and it is hoped that the industry, which already showed interest in this labeling technique, will help transitioning this promising labeling technique to the clinic.
Conclusion
The SiFA methodology has grown over the years from a niche methodology to a broadly applied labeling strategy towards innovative 18 F-labeled radiopharmaceuticals for PET. SiFA radiolabeling procedures have been methodically studied and can be easily performed using either the SiFA leaving group approach or the SiFA-IE methodology. Moreover, those approaches are now well-established for a great variety of structurally distinct high affinity probes such as peptides, proteins, affibodies, and even small ligands. The practical simplicity and mild reaction conditions of the SiFA-IE strategy in particular represents a unique advantage in 18 F-labeling which, when applied in synergy with the recently developed Munich drying method, helps meeting the requirements for a true kit-like 18 F-labeling procedure.
